The University of Oxford on Thursday (15) released a new study shows that Pfizer, Moderna’s new crown vaccine and AstraZeneca vaccine (AZ vaccine), the same, after vaccination are rare cases of cerebral thrombosis.
The AstraZeneca vaccine was recently reported in several countries, and several European countries announced a moratorium on administering it, but last week the European Medicines Agency (EMA) announced the latest assessment that the AstraZeneca vaccine is “probably” associated with rare blood clots.
While the safety of the AZ vaccine has been questioned, a new study by Oxford University on Thursday (15) showed that the Pfizer vaccine, Moderna vaccine and AZ vaccine have roughly the same chance of developing rare cerebral thrombosis.
After receiving either the Pfizer or Moderna vaccines, four out of every million people experienced symptoms of cerebral thrombosis, and five out of every million AZ vaccine subjects experienced symptoms of cerebral thrombosis.
The risk of getting cerebral thrombosis side effects was much higher in people with neocoronary pneumonia than in those who received the vaccine, i.e. 39 cases of cerebral thrombosis per 1 million people.
Although this study did not include the Joulsen vaccine, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have asked states to suspend the use of Joulsen New Crown vaccine based on concerns about blood clots, and Joulsen announced it would stop supplying the EU vaccine. the CDC held an emergency meeting on Wednesday and resolved to indefinitely extend the suspension of Joulsen vaccination.
As of deadline, Moderna (MRNA-US) was down 1.76%, Pfizer (PFE-US) was up 1.31%, Jolson (JNJ-US) was up 1.01% and Astellicom (AZN-US) was up 2.22% during Thursday’s midday trading session.
Recent Comments